Shifting Focus to Drug Development, Sialix Raises $2M, Changes Name to Siamab Therapeutics | GenomeWeb

NEW YORK (GenomeWeb) – Sialix said this week that it has raised an additional $2 million as part of its Series B round, bringing the total raised to $6 million.

The company also said that it has changed its name to Siamab Therapeutics, marking its shift from a glycomics-focused firm to one focused on developing therapeutic antibodies for cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.